Krystal Biotech (KRYS) just unveiled an update.
Jeune Aesthetics, Inc., a subsidiary of Krystal Biotech, Inc., revealed promising phase 1 trial results for KB301, a treatment for facial and décolleté wrinkles. To discuss these findings and the future of their product pipeline, the company will be hosting a detailed conference call and webcast, with additional resources available on Krystal Biotech’s website. This announcement is expected to excite investors and market watchers keen on the latest biotech advancements and their potential market impacts.
See more insights into KRYS stock on TipRanks’ Stock Analysis page.
